Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline

Hull, 2002, Cancer control with radical prostatectomy alone in 1,000 consecutive patients, J Urol, 167, 528, 10.1016/S0022-5347(01)69079-7 Kupelian, 1996, Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer, Urology, 48, 249, 10.1016/S0090-4295(96)00167-7 Stephenson, 2005, Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy, J Clin Oncol, 23, 7005, 10.1200/JCO.2005.01.867 Calais, 2018, 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/ml: impact on salvage radiotherapy planning, J Nucl Med, 59, 230, 10.2967/jnumed.117.201749 Rouvière, 2010, Imaging of prostate cancer local recurrences: why and how?, Eur Radiol, 20, 1254, 10.1007/s00330-009-1647-4 Michalski, 2010, Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer, Int J Radiat Oncol Biol Phys, 76, 361, 10.1016/j.ijrobp.2009.02.006 Poortmans, 2007, Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group, Radiother Oncol, 84, 121, 10.1016/j.radonc.2007.07.017 Wiltshire, 2007, Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy, Int J Radiat Oncol Biol Phys, 69, 1090, 10.1016/j.ijrobp.2007.04.068 Sidhom, 2008, Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group, Radiother Oncol, 88, 10, 10.1016/j.radonc.2008.05.006 Lawton, 2009, RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 74, 383, 10.1016/j.ijrobp.2008.08.002 Staffurth, 2005, Target volume definition for intensity modulated whole pelvic radiotherapy (IMWPRT), Int J Radiat Oncol Biol Phys, 63, S332, 10.1016/j.ijrobp.2005.07.570 Harris, 2015, Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy, Int J Radiat Oncol Biol Phys, 92, 874, 10.1016/j.ijrobp.2015.03.021 Sargos, 2015, Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU), Cancer Treat Rev, 41, 814, 10.1016/j.ctrv.2015.10.005 Pollack, 2022, The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial, Lancet, 399, 1886, 10.1016/S0140-6736(21)01790-6 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Schiller, 2021, PSMA-PET/CT-based lymph node atlas for prostate cancer patients recurring after primary treatment: clinical implications for salvage radiation therapy, Eur Urol Oncol, 4, 73, 10.1016/j.euo.2020.04.004 Hall, 2021, NRG Oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer, Int J Radiat Oncol Biol Phys, 109, 174, 10.1016/j.ijrobp.2020.08.034 Fendler, 2017, 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0, Eur J Nucl Med Mol Imaging, 44, 1014, 10.1007/s00259-017-3670-z Eder, 2012, 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging, Bioconj Chem, 23, 688, 10.1021/bc200279b Borm, 2019, FDG/PET-CT-based lymph node atlas in breast cancer patients, Int J Radiat Oncol Biol Phys, 103, 574, 10.1016/j.ijrobp.2018.07.2025 Vogel, 2021, Feasibility and outcome of PSMA-PET-based dose-escalated salvage radiotherapy versus conventional salvage radiotherapy for patients with recurrent prostate cancer, Front Oncol, 11, 715020, 10.3389/fonc.2021.715020 Emmett, 2017, Treatment outcomes from 68Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET, J Nucl Med, 58, 1972, 10.2967/jnumed.117.196683 Emmett, 2020, 3-Year freedom from progression after 68Ga-PSMA PET/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial, J Nucl Med, 61, 866, 10.2967/jnumed.119.235028 Schmidt-Hegemann, 2019, Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis, J Nucl Med, 60, 227, 10.2967/jnumed.118.212563 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Jani, 2021, 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial, Lancet, 397, 1895, 10.1016/S0140-6736(21)00581-X Buyyounouski, 2017, Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 245, 10.3322/caac.21391 Barbosa, 2019, Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread, RadioGraphics, 39, 186, 10.1148/rg.2019180079 Filimonova, 2021, The distribution of pelvic nodal metastases in prostate cancer reveals potential to advance and personalize pelvic radiotherapy, Front Oncol, 10, 590722, 10.3389/fonc.2020.590722 Harmon, 2021, Validating modern NRG Oncology pelvic nodal and Groupe Francophone de Radiothérapie Urologique prostate bed contouring guidelines for post-prostatectomy salvage radiation: a secondary analysis of the LOCATE trial, Int J Radiat Oncol Biol Phys, 111, 1195, 10.1016/j.ijrobp.2021.05.009 Onal, 2020, Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients, Radiother Oncol, 151, 222, 10.1016/j.radonc.2020.08.021 Hegemann, 2016, Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment, Radiat Oncol, 11, 37, 10.1186/s13014-016-0615-9 Maurer, 2019, 99mTechnetium-based prostate-specific membrane antigen–radioguided surgery in recurrent prostate cancer, Eur Urol, 75, 659, 10.1016/j.eururo.2018.03.013 Perera, 2016, Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021 Pfister, 2014, Early salvage radiotherapy following radical prostatectomy, Eur Urol, 65, 1034, 10.1016/j.eururo.2013.08.013 Stephenson, 2007, Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy, J Clin Oncol, 25, 2035, 10.1200/JCO.2006.08.9607 Fendler, 2019, Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial, JAMA Oncol, 5, 856, 10.1001/jamaoncol.2019.0096 Byrne, 2018, Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET, Radiother Oncol, 126, 244, 10.1016/j.radonc.2017.10.022 Gonzalez-Moya, 2022, Mapping of recurrence sites following adjuvant or salvage radiotherapy for prostate cancer patients, Front Oncol, 11, 787347, 10.3389/fonc.2021.787347